These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26467273)

  • 21. Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes.
    Lebdai S; Bigot P; Leroux PA; Berthelot LP; Maulaz P; Azzouzi AR
    J Urol; 2017 Aug; 198(2):335-344. PubMed ID: 28322857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.
    Koudinova NV; Pinthus JH; Brandis A; Brenner O; Bendel P; Ramon J; Eshhar Z; Scherz A; Salomon Y
    Int J Cancer; 2003 May; 104(6):782-9. PubMed ID: 12640688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
    Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
    Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Photodynamic therapy for prostate cancer--a review of current status and future promise.
    Moore CM; Pendse D; Emberton M
    Nat Clin Pract Urol; 2009 Jan; 6(1):18-30. PubMed ID: 19132003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: TOOKAD® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Cadeddu JA
    J Urol; 2014 May; 191(5):1290. PubMed ID: 24745491
    [No Abstract]   [Full Text] [Related]  

  • 26. Re: TOOKAD ® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Taneja SS
    J Urol; 2014 Apr; 191(4):983-4. PubMed ID: 24703118
    [No Abstract]   [Full Text] [Related]  

  • 27. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker.
    Plaks V; Koudinova N; Nevo U; Pinthus JH; Kanety H; Eshhar Z; Ramon J; Scherz A; Neeman M; Salomon Y
    Neoplasia; 2004; 6(3):224-33. PubMed ID: 15153334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
    Sjoberg HT; Philippou Y; Magnussen AL; Tullis IDC; Bridges E; Chatrian A; Lefebvre J; Tam KH; Murphy EA; Rittscher J; Preise D; Agemy L; Yechezkel T; Smart SC; Kinchesh P; Gilchrist S; Allen DP; Scheiblin DA; Lockett SJ; Wink DA; Lamb AD; Mills IG; Harris A; Muschel RJ; Vojnovic B; Scherz A; Hamdy FC; Bryant RJ
    Br J Cancer; 2021 Aug; 125(4):534-546. PubMed ID: 34155340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Photodynamic therapy for prostate cancer - A narrative review.
    Osuchowski M; Bartusik-Aebisher D; Osuchowski F; Aebisher D
    Photodiagnosis Photodyn Ther; 2021 Mar; 33():102158. PubMed ID: 33352313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of photochemical internalisation using disulfonated chlorin and porphyrin photosensitisers: An in vitro study in 2D and 3D prostate cancer models.
    Martinez de Pinillos Bayona A; Woodhams JH; Pye H; Hamoudi RA; Moore CM; MacRobert AJ
    Cancer Lett; 2017 May; 393():68-75. PubMed ID: 28223166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice.
    Neuschmelting V; Kim K; Malekzadeh-Najafabadi J; Jebiwott S; Prakash J; Scherz A; Coleman JA; Kircher MF; Ntziachristos V
    Theranostics; 2018; 8(3):723-734. PubMed ID: 29344301
    [No Abstract]   [Full Text] [Related]  

  • 32. Photodynamic therapy for prostate cancer--an emerging approach for organ-confined disease.
    Moore CM; Emberton M; Bown SG
    Lasers Surg Med; 2011 Sep; 43(7):768-75. PubMed ID: 22057504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes.
    Berdugo M; Bejjani RA; Valamanesh F; Savoldelli M; Jeanny JC; Blanc D; Ficheux H; Scherz A; Salomon Y; BenEzra D; Behar-Cohen F
    Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1633-44. PubMed ID: 18385085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad.
    Madar-Balakirski N; Tempel-Brami C; Kalchenko V; Brenner O; Varon D; Scherz A; Salomon Y
    PLoS One; 2010 Apr; 5(4):e10282. PubMed ID: 20421983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer.
    Huang Z; Chen Q; Luck D; Beckers J; Wilson BC; Trncic N; Larue SM; Blanc D; Hetzel FW
    Lasers Surg Med; 2005 Jun; 36(5):390-7. PubMed ID: 15856509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity.
    Preise D; Oren R; Glinert I; Kalchenko V; Jung S; Scherz A; Salomon Y
    Cancer Immunol Immunother; 2009 Jan; 58(1):71-84. PubMed ID: 18488222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prompt assessment of WST11-VTP outcome using luciferase transfected tumors enables second treatment and increase in overall therapeutic rate.
    Fleshker S; Preise D; Kalchenko V; Scherz A; Salomon Y
    Photochem Photobiol; 2008; 84(5):1231-7. PubMed ID: 18399928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies.
    Nogueira L; Tracey AT; Alvim R; Reisz P; Scherz A; Coleman JA; Kim K
    Molecules; 2020 Nov; 25(22):. PubMed ID: 33228126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Focal Laser Ablation and Photodynamic Vascular Therapy with soluble TOOKAD® in the treatment of low risk prostate cancer].
    Domínguez-Escrig JL; Casanova Ramón-Borja J
    Arch Esp Urol; 2016 Jul; 69(6):327-36. PubMed ID: 27416636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel photodynamic therapy for drug-resistant prostate cancer cells using porphyrus envelope as a novel photosensitizer.
    Yamauchi M; Honda N; Hazama H; Tachikawa S; Nakamura H; Kaneda Y; Awazu K
    Photodiagnosis Photodyn Ther; 2014 Mar; 11(1):48-54. PubMed ID: 24629697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.